AIM AIM ImmunoTech Inc.
Biological Products, (No Diagnostic Substances) · NYSE · SEC CIK 946644 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY-18.8%
TTM net income YoY10.3%
TTM EPS YoY93.4%
Revenue 3-yr CAGR-22.2%
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin-12,800.0%
Net margin-15,526.4%
FCF margin—
EBITDA margin-11,853.8%
Returns
ROE-2,828.6%
ROA-185.4%
ROIC (approx.)—
Asset turnover0.01x
Leverage & solvency
Liabilities / assets27.4%
Debt / equity0.41x
Current ratio2.75x
Interest coverage-9.33x
Cash quality & payout
Operating cash flow / net income0.87x
Accruals ratio-25.0%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 |
|---|---|---|
| Income statement | ||
| Revenue | $88,000 | $170,000 |
| R&D expense | $3.92M | $6.20M |
| SG&A expense | $7.70M | $13.71M |
| Operating income | -$11.66M | -$19.77M |
| Interest expense | $812,000 | $585,000 |
| Pretax income | -$13.96M | — |
| Net income | -$13.96M | -$17.32M |
| EBITDA | -$11.63M | -$19.73M |
| EPS (basic) | -8.62 | -30.92 |
| EPS (diluted) | -8.62 | -30.92 |
| Weighted avg. shares (diluted) | 1.62M | 560,169 |
| Balance sheet | ||
| Cash & equivalents | $2.98M | $1.70M |
| Short-term investments | $62,000 | $2.28M |
| Receivables | $7,000 | — |
| Current assets | $3.29M | $4.18M |
| PP&E, net | $71,000 | $108,000 |
| Intangibles | $1.66M | $2.59M |
| Total assets | $5.78M | $8.61M |
| Current liabilities | $6.22M | $9.54M |
| Short-term debt | $3.55M | $2.31M |
| Long-term debt | $927,000 | $2.81M |
| Total debt | $4.48M | $5.11M |
| Total liabilities | $15.56M | $9.93M |
| Shareholders' equity | -$9.78M | -$1.32M |
| Net debt | $1.49M | $3.41M |
| Shares outstanding | 3.07M | 655,262 |
| Cash flow statement | ||
| Operating cash flow | -$10.96M | -$14.89M |
| Capital expenditure | — | $18,000 |
| Free cash flow | — | -$14.91M |
| Investing cash flow | $1.85M | $4.71M |
| Financing cash flow | $10.39M | $6.44M |
| Depreciation & amortization | $37,000 | $37,000 |
| Stock-based compensation | $60,000 | $686,000 |
Free plan shows the latest 2 periods; Pro shows all 17 🔒
· This company does not report gross profit in XBRL.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.